Society of Gynecologic Oncology (SGO)

Study results show that women who carry a BRCA1 mutation have a shorter reproductive lifespan than n

Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma

By

James Nam, PharmD

March 24, 2018

Researchers randomly assigned 74 patients to receive everolimus plus letrozole daily or tamoxifen daily plus medroxyprogesterone daily on alternating weeks.

Socioeconomic status, including education and income level, appears to be tied to prostate-specific

Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers

By

Jonathan Goodman, MPhil

March 24, 2018

The impact of the ACA on health insurance access among women diagnosed with a gynecologic cancer was previously unestablished.

Mixed data highlight the need for researchers to conduct studies to understand the clinical, rather

Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery

By

James Nam, PharmD

March 24, 2018

There were no reported changes in pain scores after surgery.

Embracing all the myriad variations of the human genome should, in theory, lead to rewards that all

Hypermethylation of DNA Repair Genes in Ovarian Carcinoma

By

Andrea S. Blevins Primeau, PhD, MBA

March 15, 2017

Hypermethylation of HRR-associated genes was not associated with improved survival in ovarian cancer.

CD86-positive pDCs are known to regulate T cell activation, and previous data suggest that T cells c

Sentinel Lymph Node Mapping Cost-effective in Endometrial Carcinoma

By

Andrea S. Blevins Primeau, PhD, MBA

March 15, 2017

Study data suggest that SLN mapping is more cost-effective and more efficacious than routine LND or selective LND.

No differences in overall survival time and quality of life in elderly and/or frail patients with ne

Elderly Patients and Treatment Tolerance in Phase 1 Trials

By

Andrea S. Blevins Primeau, PhD, MBA

March 15, 2017

Study results suggest that carefully selected elderly patients with recurrent or refractory gynecologic malignancy should be enrolled in phase 1 trials.

Olanzapine, an antipsychotic, significantly improves nausea and vomiting in chemotherapy patients, a

Patients With Ovarian Cancer Rank Nausea as Most Concerning Chemotherapy Side Effect

By

Andrea S. Blevins Primeau, PhD, MBA

March 15, 2017

Patients with newly diagnosed ovarian cancer rank nausea as the most concerning side effect associated with chemotherapy.

A decision model finds that the higher cost of new sequencing methods is justified by their clinical

Combined Liquid Pap and CT-DNA Testing May Detect Ovarian Cancer

By

Andrea S. Blevins Primeau, PhD, MBA

March 15, 2017

Combined liquid-based Pap and CT-DNA may be a new method for tumor-derived driver mutation screening in primary ovarian carcinoma.

A substantial proportion of patients with rectal cancer managed by the watch-and-wait approach avoid

Reduction Strategies Improve Surgical Site Infection Rate After Colon Surgery

By

Andrea S. Blevins Primeau, PhD, MBA

March 14, 2017

The results of this study show that implementation of strategies to reduce SSI can improve SSI rates, despite risk factors for infection.

In an older population with colorectal cancer, adding irinotecan to first-line infusional fluorourac

Chemotherapy Fails To Prolong Survival in Low-grade Serous Ovarian Cancer

By

Andrea S. Blevins Primeau, PhD, MBA

March 14, 2017

Adjuvant platinum-based chemotherapy did not improve survival in women with low-grade serous ovarian cancer.

Next post in SGO 2017

CRS and HIPEC appear to have promising data when used in the optimal patient population.

Adjuvant Chemotherapy Without Radiation Effective in Stage IB-IIA Cervical Cancer